SOURCE: Boston Therapeutics
MANCHESTER, NH--(Marketwire - Nov 29, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that David Platt, Ph.D., Chief Executive Officer, is presenting a corporate update at the SeeThruEquity Smallcap & Microcap Investor Summit at the Cornell Club in New York City on December 4th, 2012.
"We have made good progress on SUGARDOWN® and PAZ320 this year and have laid a solid foundation as we ramp up operations for 2013," said Dr. Platt. "The recent addition of Jonathan Rome as our Chief Operating Officer will help accelerate the commercialization of SUGARDOWN® and the filing of an Abbreviated New Drug Application (ANDA) for BTI-7, a new, chewable dosage form of the diabetes drug metformin hydrochloride."
- The Company recently completed an open label, dose escalation crossover Phase ll study on Type 2 diabetic patients at Dartmouth Hitchcock Medical Center for PAZ320. Trial results are expected to be published in a peer-reviewed journal.
- SUGARDOWN® sales increased approximately 700% in the first nine months of 2012 compared with the same period in 2011
- The FDA approved our petition to File an ANDA for BTI-7 to treat diabetes
- Jonathan B. Rome, former CEO of ThePharmaNetwork, who was recently named Chief Operating Officer, invested $625,000 in the Company's S-1 financial offering
About Boston Therapeutics, Inc.
Boston Therapeutics, a pharmaceutical company headquartered in Manchester, NH (OTCQB: BTHE) is a leader in the field of complex carbohydrate drug design. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes. The pipeline includes: SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement tablet designed to moderate post-meal blood glucose; BTI-7, a new, chewable dosage form of the diabetes drug metformin hydrochloride; PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation; and IPOXYN™, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com and www.sugardown.com.
The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements. This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission.